Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2004

View Archived Issues

Crucell presents human anti-OX40 receptor agonistic antibodies for cancer therapy

Novel PEPCK inhibitors and their use in type 2 diabetes reported by Roche

Novuspharma team identifies new VEGF production inhibitors

Novel PARP inhibitors prepared and tested at Pfizer

Merck and Isis present new NS5B inhibitors for use in HCV infection

New analgesic bradykinin B1 antagonists in early development at Fournier

Novel antiangiogenic agents covered by Pfizer patent

New vitamin D-based CYP24 inhibitors and their use claimed by Johns Hopkins U. and Cytochroma

Enrollment ceased in phase IIb/III trial of Ad5FGF-4

Expert advisory board to guide BioMarin's PKU programs

A-221-HIV to enter clinical trials in Latin America

CAT continues progress in 2004

Inspire to conduct additional trial for diquafosol following FDA meeting

Takeda exercises rights to ATL-962 for Japan

Novartis files global applications for new Diovan indication

CE Mark for Celacade for chronic heart failure

Genencor hepatitis B vaccine to enter phase I this month

sNDA for intravenous administration of Remodulin

Bentley completes phase I study of proprietary intranasal insulin formulation

Botulinum toxin B reported to improve drooling in Parkinson's disease

Further evidence for the therapeutic benefits of thalidomide in cutaneous sarcoidosis

Survival benefit found with tesmilifene plus doxorubicin in recurrent/metastatic breast cancer

Alendronate found effective in the prevention of bone disease in patients with cystic fibrosis

Promising effects induced by ziprasidone in Huntington's disease

FDA approval for Spiriva HandiHaler

NDA submission for YM-087 for hyponatremia

European submission for YM-617 TOCAS

Approvable letter for Emsam

ECO-04601 inhibits tumor growth in animal model of glioma

Pfizer files IND for antibody product candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.